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(57) ABSTRACT 
A computing device-controlled system is described for the 
generation of amplitude-modulated pulse-width modulation 
(AMPWM) signals for use in treating neurological dysfunc 
tion via cranial neurostimulation, where the AMPWM signal 
is specifically designed to minimize the electrical impedance 
of the tissues of the head. A low-frequency carrier signal is 
determined for the AMPWM signal by measuring EEG activ 
ity at a reference site or sites, generally corresponding with 
the location of Suspected brain dysfunction. Carrier signal 
frequency is variably related to critical frequency compo 
nents of the EEG power spectral density, determined from 
statistical analysis of amplitudes and variability, and dynami 
cally changed as a function of time to prevent entrainment. 
The AMPWM signal is presented to a subject via a plurality of 
neurostimulation delivery modes for therapeutic use. 
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/ y 
Biopotential Circuit 0. 
Acquisition Nuretical / 




isolated Power Supply 






US 8,280,502 B2 
Page 2 
U.S. PATENT DOCUMENTS 6,350,275 B1 2/2002 Vremain et al. 
6,480,743 B1 1 1/2002 Kirkpatricket al. 5,392,788 A 2/1995 Hudspeth sw 
5,571,150 A 1 1/1996 Wernicke et al. 2001/0003799 A1 6/2001 Boveja 
5,611,350 A 3, 1997 John 2001/OOOT950 A1 7/2001 North et al. 
5,720,744 A 2/1998 Eggleston et al. 
6,016,449 A 1/2000 Fischell et al. FOREIGN PATENT DOCUMENTS 
6,066,163 A 5, 2000 John WO WO-01 (26.232 A2 4, 2001 
6,081,743 A 6, 2000 Carter et al. k . 
6,246,912 B1 6/2001 Sluijter et al. cited by examiner 





U.S. Patent Oct. 2, 2012 Sheet 2 of 4 US 8,280,502 B2 
Pulse width 
?teel 
t-r PERIOD of signal 





U.S. Patent Oct. 2, 2012 Sheet 3 of 4 US 8,280,502 B2 
FIGURE 3 
: - 2 
Resistor 
4 
7 Capacitor / 5 
6 FE 
  
US 8,280,502 B2 Sheet 4 of 4 Oct. 2, 2012 U.S. Patent 
  
US 8,280,502 B2 
1. 
METHOD AND APPARATUS FOR UTILIZING 
AMPLITUDE-MODULATED PULSE-VIDTH 
MODULATION SIGNALS FOR 
NEUROSTIMULATION AND TREATMENT OF 
NEUROLOGICAL DISORDERS USING 
ELECTRICAL STMULATION 
CROSS REFERENCE TO RELATED PATENT 
DOCUMENTS 
This application is a divisional application of U.S. patent 
application Ser. No. 1 1/490,255, filed Jul. 21, 2006 now U.S. 
Pat. No. 7,715,910, which is a continuation application of 
U.S. patent application Ser. No. 10/357,503, filed Feb. 4, 
2003 now abandoned, which is based upon and claims the 
benefit of priority from U.S. Provisional Application No. 
60/353,234, filed on Feb. 4, 2002. The disclosures of the prior 
applications are hereby incorporated by reference herein in 
their entirety. 
FIELD OF THE INVENTION 
The present invention relates generally to the field of pro 
ducing and applying electrical energy to the brain, and to the 
therapeutic uses of the electrical energy and an apparatus for 
administering the same. More specifically, the present inven 
tion relates to a system for controlling neurostimulation 
where the neurostimulation comprises an electrical signal 
whose characteristics minimize composite tissue impedances 
of the head, and more specifically yet, to a computer con 
trolled system for automatic adjustment of neurostimulation 
signals related to critical frequency components of an 
acquired EEG signal, generally obtained at or near a region of 
Suspected brain dysfunction. 
The electrical activity, or EEG, of human brains has tradi 
tionally been used as a diagnostic marker for abnormal brain 
function and related symptomatic dysfunction. Often, trau 
matic disturbances such as mechanical injury, Social stress, 
emotional stress and chemical exposure cause neurophysi 
ological changes that will manifest as EEG abnormalities. 
However, disruption of this abnormal EEG activity by the 
application of external electrical energy, henceforth referred 
to as a neurostimulation signal, may cause yet further neuro 
physiological changes in traumatically disturbed brain tis 
Sues, as evidenced in an amelioration of the EEG activity, and 
hence are beneficial to an individual. Such therapeutic inter 
vention has proven useful in pain therapy and in treating a 
number of non-painful neurological deficits such as depres 
Sion, attention deficit disorder, and many others. 
BACKGROUND OF INVENTION AND 
DESCRIPTION OF RELATED ART 
In the 1960s and early 1970s, Robert Monroe of the 
Monroe Institute of Applied Sciences explored the effects of 
Sound on the brain and discovered that he could produce a 
driving or entrainment of brain waves. Dr. Gerald Oster, a 
biophysicist, also investigating the effects of Sound on the 
brain, discovered that pulsations called binaural beats 
occurred in the brain when tones of different frequencies were 
presented separately to each ear. The beat frequency equals 
the frequency difference between the two tones. Both Monroe 
and Oster began using electronic oscillators to provide tones 
with frequency, purity and intensity that can be precisely 
controlled. 
U.S. Pat. No. 3,884,218 to Robert A. Monroe shows a 














ing Sound with a delta-rhythm signal that is referred to as an 
“EEG sleep signal.” The 218 patent uses sound to induce 
sleep by creating a specific signal that coaxes the brain into a 
relaxed state. This signal chosen in the 218 patent is chosen 
based upon its proximity to signals that are strong during 
normal sleep. 
U.S. Pat. No. 4,191,175 to Nagle shows a method and 
apparatus for repetitively "producing a noise-like signal for 
inducing a hypnotic or anesthetic effect . . . . by creating 
frequency bursts of digital pulses that are then passed through 
a pink noise filter to eliminate frequencies above a certain 
cut-off. The resultant signal is then passed through a band 
pass filter and used to drive an audible signal source. 
An apparatus for electrophysiological stimulation is shown 
in U.S. Pat. No. 4,227,516 to Meland et al. in which a first 
signal above the delta-beta frequency range is modulated by 
signal within that range and applied to electrodes on the 
forehead of a user. 
A learning-relaxation device of U.S. Pat. No. 4,315.502 
has both lights for pulsing signals and sound means for a 
pulsing Sound signal as well as a control means that can 
individually vary the light and Sound signals. 
U.S. Pat. No. 4,834,701 to Masaki shows a device similar 
to those used by Monroe and Oster with first and second 
generators with frequencies above 16 hertz and a frequency 
difference of 4 to 16 hertz sounded to lower the brain wave 
frequency of a user. The term “entrainment” began to be 
accepted for such devices: “This phenomenon, in which one 
regular cycle locks into another, is now called entrainment, or 
mode locking.” (Gleick, Chaos: Making of a New Science 
1987, Penguin Books, p. 293). An article entitled “Alpha 
Brain Waves & Biofeedback Training in the December 1972 
Popular Electronics show a system that uses a person's own 
EEG signal to modulate a tone generator which, in turn, then 
drives a speaker heard by the same person. The device 
allowed a person to “hear his or her own brain signals in an 
attempt to Voluntarily control the frequency. A similar device 
that allows a person to “see' his or her own brain waves is 
shown in an article entitled “Mind Power: Alpha' in the July 
1976 Radio-Electronics. 
U.S. Pat. No. 5,036,858 to John L. Carter, Harold L. Rus 
sell and Len Ochs shows the use of EEG electrodes attached 
to the head of the user along with an amplifier for determining 
a current brain wave frequency of a user, which is communi 
cated to a computer processor. A new frequency is generated 
which is between the current brain wave frequency and a 
desired brain wave frequency and is within a predetermined 
range of the current brain wave frequency. This has become 
known as electroencephalographic entrainment feedback if it 
is used to “lock” the current brain wave frequency into a 
desired frequency. 
U.S. Pat. No. 5,365,939 to Len Ochs provides a method of 
“exercising the brain by using a device producing audio and 
visual stimulation to move a user's brain wave frequency 
back and forth between predetermined frequency levels. 
In U.S. Pat. No. 6,081,743 to John L. Carter, Harold L. 
Russell, W. Daniel Vaughn and Robert R. Austin, a method for 
treating an individual is described by determining a brain 
wave frequency which corresponds to a highest evoked 
response of the individual, entraining the brain wave fre 
quency to the brain wave frequency corresponding to the 
highest evoked response, and then maintaining the brainwave 
at that frequency for a predetermined length of time. The 
highest evoked response is described as the highest EEG 
response or the highest cerebral blood flow (CBF) of the 
individual or even some other measure. 
US 8,280,502 B2 
3 
Two patents in application at the time of the disclosure of 
the present invention relate to the present invention. In Appli 
cation No. 20010003799 by Birinder B. Boveja an apparatus 
and method for adjunct (add-on) therapy utilizing an external 
stimulator is described to stimulate a cranial nerve according 
to a predetermined program. 
In Application No. 20010007950 by Richard B. North et. 
al. a neurostimulation system and method is described that 
includes an implantable stimulator and patient interactive 
computer. Also, the 950 application requires patient interac 
tion. 
Prior methods of neurostimulation for therapeutic pur 
poses have in many ways attempted to ameliorate brain func 
tioning by providing the brain with electrical energy that is 
designed to be a reflection of the brain's own activity, often 
with the intent of modifying the brain electricity to follow, or 
entrain to, a desired frequency, range of frequencies, or rela 
tionship among frequencies, or alternately to target theoreti 
cally and empirically derived frequency states as a goal of 
training ortherapy. However, little attention has been given to 
signal design for overcoming the complex and composite 
impedance presented by the tissues of the head. Such signals, 
when properly constructed, will limit attenuation of neuro 
stimulation signals for improved effectiveness in patient 
treatment. 
Regarding the concept of conductivity, it is known that the 
tendency of any conductive material to limit the flow of 
electrical charge, otherwise known as electrical current, is 
known as impedance. In general terms, attenuation of current 
flow is proportional to the magnitude of a material’s imped 
ance. The impedance of a Substance is a function of its mate 
rial and physical properties. Environmental factors, such as 
temperature, also influence the impedance of a material. Most 
significant to the disclosure of the present invention is the 
relationship between impedance of a material and the fre 
quency of the electrical signal being conducted through the 
material. 
In its most fundamental terms, three electrical effects gov 
ern impedance: resistance, capacitance and inductance. 
Resistance is a fundamental form of impedance that is con 
stant intime. Therefore, the frequency of a signal has no effect 
on resistance. However, both capacitive and inductive effects 
are functions of frequency. Inductive reactance, the formal 
name for impedance due to inductance, is proportional to 
frequency. Thus, the higher the frequency of a signal is, the 
higher will its corresponding inductive reactance be. Capaci 
tive reactance, the formal name for impedance due to capaci 
tive effects, is inversely proportional to frequency. Thus, as a 
signals frequency increases, the impedance of a material due 
to capacitance decreases. For very high frequencies, capaci 
tive reactance can become very small, and the resulting 
attenuation of the flow of current will be correspondingly 
less. 
The head is comprised of a series of tissues that can be 
approximately thought of as composite layers Surrounding 
the brain. Specifically, these layers of tissue include the der 
mal layers of the scalp, the skull, the meninges, the cerebral 
spinal fluid that bathes the brain, and the brain itself including 
both healthy tissues and unhealthy tissues such as lesion 
matterforming in the region of damage. The impedance of the 
tissues of the head is known to be complex in nature, that is, 
they have both a resistive component and a capacitive com 
ponent. Thus, the overall impedance of these tissues will be a 
function of signal frequency because of capacitive reactance, 













account for this fact. Because of the nature of this impedance, 
a higher frequency signal will pass through the tissues with 
much less attenuation. 
SUMMARY OF THE INVENTION 
The present invention is based on the discovery that certain 
neurostimulation signals can provide an optimal effect on the 
tissues of the brain, while eliminating conscious patient per 
ception of the signal. 
Thus, the invention is directed towards a method of treating 
one or more neurological dysfunctions. The method com 
prises taking a first measurement of the EEG of a subject 
afflicted with at least one type of the neurological dysfunction 
in order to obtain EEG results and evaluating the EEG results 
to determine whether any region of the subject's brain pos 
sesses irregular activity as compared to other regions of the 
Subject's brain. A determination of a dominant frequency is 
separately made for each of the regions of the subjects brain 
that possess irregular activity by examining the EEG results 
from each the regions of the Subject's brain that possess 
irregular activity. Finally, the method comprises an adminis 
tration of an anti-neurological dysfunction therapy to the 
Subject. The anti-neurological dysfunction therapy comprises 
inducing a neurostimulation signal directed to the regions of 
the Subject's brain that possess irregular activity for a time 
sufficient to normalize the EEG of the regions of the subjects 
brain that possess irregular activity. Additionally, further 
EEG measurements from the regions of the subjects brain 
that possess irregular activity are monitored during the 
administration of the therapy and the neurostimulation signal 
is adjusted based on any detected changes in the additional 
EEG measurements. 
The invention is also directed to an apparatus for neuro 
stimulating a Subject. The apparatus comprises a computing 
device that is operatively coupled to a neurostimulator, and a 
series of EEG sensors that are coupled to the neurostimulator. 
The EEG sensors are configured (1) to be attached to the 
subject, (2) to monitor EEG results of a subject, and (3) to 
administer neurostimulation signals to the Subject. Addition 
ally, the EEG sensors preferably comprise at least one posi 
tive contact, at least one negative contact, and at least one 
ground contact. 
In accordance with the disclosure herein, an object of the 
present invention is to generate an electrical signal for the 
purposes of neurostimulation that also minimizes the effect of 
tissue impedance to the improved flow of electrical energy to 
body tissues. 
It is a further object to pass extremely low power signals 
with minimal attenuation into Subjects who possess a high 
sensitivity to neurostimulation signals. 
It is a further object to use an electrical signal referred to as 
an amplitude-modulated pulse-width modulation 
(AMPWM) signal. An AMPWM signal is characterized by a 
high frequency component that is modulated by a low fre 
quency carrier for stimulation purposes. 
It is a further object to use pulse-width modulation and/or 
amplitude control of the high frequency component of the 
AMPWM signal in order to control the electrical energy level 
present in a neurostimulation signal. 
It is a further object of the present invention to use an 
AMPWM signal in neurostimulation in order to disentrain an 
EEG signal. Disentrainment involves the prevention of the 
EEG signal from locking into a particular frequency or fre 
quency range, and to cause, rather, the redistribution of EEG 
spectral energy. Additionally, it is an object of the present 
invention for the AMPWM signal to not maintain a given 
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frequency for a period of time Sufficient to cause dysfunc 
tional entrainment such as that which occurs in an epileptic 
seizure. 
A further object of the present invention is to provide a 
means of constantly assessing power spectral density or other 
frequency related Statistics of EEG signals, and using the 
frequency related Statistics from the EEG signals to manage 
the low frequency component of an AMPWM neurostimula 
tion signal so as to prevent entrainment to any specific fre 
quency, and to distribute energy uniformly. 
A further object is to provide a means of entraining EEG 
signals by controlling the low-frequency component of an 
AMPWM neurostimulation signal. 
A further object is to provide a means of controlling the low 
frequency component of an AMPWM signal so that the fre 
quency of the low frequency component is determined as a 
function of either a constant offset in time or a frequency 
analysis driven offset determined as a function of time. 
Another object of the present invention is to provide a 
means of delivering a neurostimulation signal to regions of 
the scalp corresponding to suspected regions of brain dys 
function by inducing the neurostimulation signal into EEG 
sensors that are concurrently used for measurement of EEG 
signals. 
Another object of the present invention is to provide neu 
rostimulation in which electrical currents are passed through 
Suspected regions of brain dysfunction through EEG sensors 
which are placed in a manner so that the region of the brain of 
the subject in which a dysfunction is located is in the area of 
placements of EEG sensors. 
Another object is to provide for the utilization of an 
AMPWM signal for delivery of neurostimulation through a 
photic means, such as rapid pulsing of light-emitting diodes, 
in which the light intensity is controlled by pulse width modu 
lation of the high frequency component of the AMPWM 
signal. 
Another object of the present invention is to provide a 
means of modifying the low-frequency component of an 
AMPWM signal to relate to frequency components of EEG 
signals, the means being accomplished by any number of 
frequency analysis techniques. 
Another object is to provide a system for neurostimulation 
that includes a means for acquiring EEG signals from a Sub 
ject, analyzing the EEG signals for frequency components 
and generating an AMPWM signal which is delivered to the 
subject for either the disentrainment or the entrainment of 
EEG activity of the subject for therapeutic purposes. 
Another object is to provide a means of determining Sus 
pected regions of brain dysfunction in a Subject by acquiring 
EEG data from a number of scalp sites of the subject, analyz 
ing the EEG data for frequency components and assignment 
to standard bands of EEG (e.g. delta, theta, etc.), determining 
the electrical energy in each of the standard bands by analysis 
in order to determine a statistic that is a function of total power 
in the band to include but not limited to sum of amplitude, or 
root-mean-square, or root Square summation; and variability 
to include but not limited to variance or standard deviation, 
and using the statistic magnitude as a function of EEG fre 
quency range as an indicator of brain dysfunction. 
A further object is to provide for an enhanced means of 
determining brain dysfunction related to patient symptoms by 
measuring sites correlating to known systemic functions (e.g. 
pain, speech, movement) and performing the previously 














A further object is to provide a means of using the statistics 
obtained from the previously described statistical analysis to 
create a visual graphic corresponding to regions of the brain 
for comparative purposes. 
A further object of the present invention is to provide a 
means of delivering neurostimulation by using more than one 
EEG amplifier for multi-site neurostimulation, and wherein 
an AMPWM signal is delivered either via photic means or 
directly to suspected regions of brain dysfunction via EEG 
sensors operatively coupled with an EEG amplifier. 
A further object of the present invention is to provide 
methods of controlling neurostimulation signal parameters 
Such as signal energy level, frequency of the low frequency 
component of an AMPWM signal, phase offset of multiple 
signals, start time and duration through a user interface. 
A further object is to provide for selection of a neurostimu 
lation delivery mode. 
A further object is to provide a method of assuring EEG 
lead interface integrity, for both EEG acquisition purposes 
and neurostimulation purposes, by testing using an algorithm 
to analyze a measure EEG signal to determine lead interface 
integrity. This algorithm detects random electrical noise, 
which is a sign of poor interface integrity. 
A further object of the present invention is to provide 
neurostimulation for other purposes of enhancing brain activ 
ity, Such as brainwave training. 
A further object is to provide a means of correlating EEG 
data to observed events and/or perceived events by provision 
of an interface control for marking data either by a patient or 
a clinician during neurostimulation. 
These and other objects, advantages and features of this 
invention will be apparent from the following description 
taken with reference to the accompanying drawings, wherein 
is shown a preferred embodiment of the invention. 
BRIEF DESCRIPTION OF THE DRAWINGS 
FIG. 1 illustrates a view of the apparatus. 
FIG. 2 illustrates a graphic representation of the neuro 
stimulation signal. It is a representation for illustrative pur 
poses only and it is not intended to limit the scope of the signal 
used in the present invention in any way. 
FIG. 3 presents a model of the apparatus of the present 
invention in regards to tissue impedance. 
FIG. 4 illustrates another view of the apparatus. 
DETAILED DESCRIPTION OF THE PREFERRED 
EMBODIMENTS 
The present invention is directed towards a method and an 
apparatus Suitable for the treatment of neurological dysfunc 
tions. 
The term “optical unit is intended to define an apparatus 
that is used on or in close proximity to the eyes. By close 
proximity, it is meanta distance from the eyes of a Subject that 
is effective for the transmittal of a light pulse into the eyes of 
the subject. Preferably, close proximity will not exceed one 
foot in distance from the subject. The structure of the optical 
unit may be worn on the face of the patient, such as optical 
device or goggles, or it may be located in a separate structure, 
Such as a stand that is held near the face or even a hand-held 
mask. Further, the optic unit may be placed at an angle to the 
eyes of the Subject. Additionally, the optic unit may be posi 
tioned behind the subject and use mirrors or other reflective 
devices (such as a white wall) to reflect the light pulse into the 
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eyes of the subject. However, in no way is this definition 
intended to limit the ultimate structure the optical unit may 
take. 
The term “neurological dysfunction' is intended to define 
a group of disorders in which one or more regions of a Sub 
jects brain operate at frequencies which are different from 
the predetermined frequency for that region of the brain or 
from the predetermined frequencies of the other regions of the 
Subject’s brain. Examples of neurological dysfunctions 
include traumatic brain injury, post traumatic stress disorder, 
post stroke paralysis, post traumatic brain injury paralysis, 
cerebral palsy, headache, depression, post chemotherapy 
cognitive, mood and fatigue disorder, fibromyalgia, memory 
loss, coma, attention deficit disorder, etc. However, the 
present invention is not to be construed as being limited to the 
treatment of these listed examples. 
The term “irregular activity” is intended to define the EEG 
frequency of an region of the Subject’s brain which does not 
match the predetermined EEG activity of the remaining 
regions of the subjects brain. Additionally, the term “irregu 
laractivity” is also intended to define an EEG frequency of an 
region of the subject's brain that matches the EEG activity of 
the remaining regions of the Subject's brain, but with a high 
degree of variance. Irregular activity is determined by ana 
lyzing the frequency bands of the region of the brain being 
investigated and identifying eithera higher band amplitude or 
a lower band amplitude than is predetermined for that region. 
Examples of potential irregular activity include amplitude 
abnormalities in which the measured peak-to-peak micro 
volts is over 14 microvolts (abnormally high) or in which the 
measured microvolts is under 5 Volts from peak-to-peak (ab 
normally low) or possesses a standard deviation of over 3 
microvolts. However, these are examples only. One of ordi 
nary skill would recognize what a proper benchmark would 
be for each subject. 
The term “neurostimulation signal' is intended to define a 
signal transmitted by the neurostimulator to a subject for the 
purpose of normalizing the brainwave activity of regions of 
the Subject's brain that possess irregular activity. The neuro 
stimulation signal is determined on a subject by Subject basis 
and is changed in relation to a shift in the region's dominant 
frequency. There is typically a reduction in variability as EEG 
changes occur. This is evidenced by a shift in the dominant 
frequency more towards the typical frequencies and ampli 
tudes that were predetermined for that region of the subjects 
brain. 
The term “normalization' is intended to define the result of 
the administration of a neurostimulation signal to regions of 
the subjects brain that correspond to the regions of the sub 
jects brain that possess irregular activity. The neurostimula 
tion signal is intended to “normalize' or adjust the brainwave 
frequency of the regions of the Subject’s brain that possess 
irregular activity to reflect the predetermined frequency of the 
region of the subjects brain that is being treated. 
The term “dominant frequency’ is intended to define the 
frequency in the EEG measurements taken from an area of the 
Subject’s brain that possesses the highest Voltage amplitude. 
The present invention is directed towards the alleviation of 
symptoms of neurological disorders caused by irregular EEG 
activity in a subject’s brain. The alleviation of the symptoms 
is accomplished by administering a neurostimulation signal 
to the regions of the subject’s brain that are related to those 
regions of the Subject's brain that possess irregular activity. 
These related regions of the subject’s brain can include 













brain. One of skill in the neurological arts would recognize 
which regions of the brain are interrelated with other regions 
of the brain. 
For example, in one method of choosing the treatment 
sites, the choice is determined by the regions of EEG-slowing 
specific to an individual, regardless of the diagnosis. In this 
method, it is the presence and pattern of EEG-slowing at any 
of the standard neurological 10-20 sites (as selected by the 
International 10-20 EEG Site Placement Standard) that is the 
indication of the appropriateness of an region of the brain for 
treatment. The EEG-slowing pattern also determines where 
on the scalp electrodes will be placed for treatment. 
Because EEG slowing that is associated with fatigue, poor 
short-term memory, and attention problems is likely to 
involve functional deficits in the left frontal lobes of the 
brains, placing electrodes on any of the following sites is a 
reasonable directive: FP1, F7, F3, C3, F1, AF7, F5, AF3 and 
possibly temporal sites, T3 & T5 (according to the Interna 
tional 10-20 EEG Site Placement Standard). The amplitudes 
and standard deviations from the image data determine the 
order of treatment for these sites. 
The imaging data is preferably gathered by sequentially 
recording from each of 21 sites. These data are preferably 
processed through a Fast Fourier Transform (FFT) computa 
tion which produces quantitative data that shows the average 
microvolts and the standard deviation for each frequency 
component of the EEG signal at each site. A preferred method 
of treatment is to identify those sites that have the highest 
standard deviation as shown in the FFT results and treat them 
first. Treatment can be accomplished by placing two pairs of 
electrodes (one positive and one negative comprise a pair) on 
each of the four sites having the highest measured amplitudes. 
It is the unique EEG pattern of the individual, however, that 
is the key to the most efficient treatment. The determination of 
treatment sites applies to any diagnostic category of neuro 
logical dysfunction and the determination is individualized 
by the quantitative data from each individuals brainwave 
data. Therefore, it is not possible to specify a standard set of 
sites for any given, or all, diagnostic categories. However, 
there is a broad diagnostic classification called EEG-slowing 
and that this category can permit the selection of predeter 
mined sites from which to direct the treatment of choice. 
Therefore, given the above information one of ordinary skill 
would understand how to select a region of the brain for 
treatment on a subject by Subject basis. 
The neurostimulation signal is administered by modulat 
ing a high frequency component, which can be further pulse 
width modulated for control of the energy level, with a low 
frequency carrier. It is the preferred intent of the present 
invention to “disentrain the brain's electrical activity, that is, 
to not target or lock into a particular frequency, but rather to 
redistribute existing energy to all frequencies in the normal 
spectra of the brain EEG in a typically uniform manner. 
However, the present invention does not preclude the utiliza 
tion of the neurostimulation signal for the purposes of 
entrainment. 
The present invention also embodies a method of focusing 
a neurostimulation signal directly on a suspected dysfunc 
tional region of the brain. This is possible because tissue 
impedances are minimized by the design of the neurostimu 
lation signal. The neurostimulation signal possesses a greater 
ability to directly reach damaged regions of the brain rather 
than simply following the outer-most tissues around the scalp 
and thereby bypassing the damaged region of the brain. 
Another advantage is achieved by inducing the neurostimu 
lation signal directly into EEG sensors. This advantage is that 
the neurostimulation signal can be strategically placed to 
US 8,280,502 B2 
present a conduction path through the damaged region of the 
brain, while concurrently measuring the EEG signal at the 
dysfunctional regions, thus providing a direct link between 
the measured EEG signals and the neurostimulation signals 
being delivered directly to the dysfunctional region. 
A method for treating a subject with the method of the 
present invention preferably includes the generation of an 
electrical neurostimulation signal characterized by a high 
frequency pulse train modulated by a low frequency carrier 
signal. A means of providing for variable levels of electrical 
power may be accomplished by using either pulse width 
modulation of the high frequency pulse train, as in the pre 
ferred embodiment of the present invention, or variable 
amplitudes of the same pulses. Preferably, the frequency of 
the high frequency pulse train is at least one order of magni 
tude greater than the frequency of the low frequency carrier 
signal. It is preferred that the high frequency pulse be in the 
range of 43 to 1,000,000 hertz. It is more preferred that the 
high frequency pulse be in the range of 1,000 to 100,000 
hertz. It is even more preferred that the high frequency pulse 
be in the range of 10,000 to 20,000 hertz. It is most preferred 
that the high frequency pulse be 15,000 hertz. 
The low frequency carrier signal is variably related to 
critical frequency components of the EEG power spectral 
density, determined from Statistical analysis of amplitudes 
and variability. The low frequency carrier signal is deter 
mined from information obtained by measuring EEG activity 
at a reference site or sites that generally corresponds with the 
location of suspected brain dysfunction, and the low fre 
quency carrier signal is dynamically changed as a function of 
time to prevent entrainment. This is performed by changing 
the frequency offset (as described below) at predetermined 
time intervals. It is preferred that the low frequency carrier 
signal be typical of a brainwave EEG. It is more preferred that 
the low frequency carrier signal be in the range of 1-42 hertz. 
The combination of (1) the high frequency pulse train as it 
is modulated by (2) the low frequency carrier signal, hence 
forth referred to as an AMPWM signal, provides a means of 
minimizing the effect of tissue impedances of the head. How 
ever, no limitation of the present invention to AMPWM sig 
nals alone is intended by this abbreviation. Any signal that 
possess both (1) and (2) as defined above is intended to be 
encompassed by the present invention. 
In general, as will be discussed in greater detail in Subse 
quent sections of this disclosure, the electrical impedance of 
tissues of the head decreases with increased electrical signal 
frequency. Thus, the high frequency pulse train component of 
the AMPWM signal passes through the head tissues with less 
attenuation than the low frequency carrier signals typically 
used in already known neurostimulation methods. Further, 
the low frequency carrier signal component of the neuro 
stimulation signal in essence serves to turn on and off the high 
frequency signal component with a frequency that is gener 
ally related to the range of frequencies present in an EEG 
signal. Thus, the low frequency carrier signal component may 
be produced at frequencies commonly used for therapeutic 
purposes in neurostimulation devices, such as entrainment or 
disentrainment. 
Some neurological dysfunctions that may be treated by the 
present invention include traumatic brain injury, post trau 
matic stress disorder, post stroke paralysis, post traumatic 
brain injury paralysis, cerebral palsy, headache, depression, 
post chemotherapy cognitive, mood and fatigue disorder, 
fibromyalgia, memory loss, coma, attention deficit disorder, 
etc. However, this list is not intended to be exclusive. 
The method preferably comprises taking a first measure 













the neurological dysfunction in order to obtain EEG results 
and evaluating the obtained EEG results to determine whether 
any region of the Subject’s brain possesses irregular activity 
as compared to other regions of the Subjects brain. It is 
preferred that the subject be a mammal and, more preferably, 
a primate. It is most preferred that the subject be a human 
being. It is also preferred that the irregular activity be deter 
mined by comparing the EEG signals from a region of the 
subject’s brain with the EEG signals from the remaining 
regions of the subjects brain. It is also preferred that the EEG 
signals are obtained from more than one region of the Sub 
ject's scalp. It is even more preferred that the EEG signals be 
obtained from at least 21 regions of the subject’s scalp that 
correspond to 21 regions of the subjects brain. It is preferred 
that the regions be selected according to the International 
10-20 EEG Site Placement Standard. 
A determination of a dominant frequency of the Subjects 
brain is made from the evaluating the EEG results from the 
regions of the Subject's brain that possess irregular activity. 
Preferably, the evaluation involves the correlation of the EEG 
signals into a graphic image of the Subject's brain. Even more 
preferably, the graphic image is evaluated and new EEG 
signals from the Subject's brain are taken in order to ensure 
that the first EEG signals were accurate and in order to deter 
mine a dominant frequency from the regions of the Subjects 
brain that have been confirmed as possessing irregular activ 
ity. 
Finally, the method comprises an administration of an anti 
neurological dysfunction therapy to the Subject. The anti 
neurological dysfunction therapy comprises inducing a neu 
rostimulation signal directed to the regions of the Subjects 
brain that possess irregular activity for a time sufficient to 
normalize the EEG signals of the regions of the subjects 
brain that possess irregular activity. 
It is preferred that the time be between one second and one 
hour. It is more preferred that the time be between 1 and 30 
minutes. It is even more preferred that the time is between 1 
minute and 10 minutes. It is even more preferred still that the 
time be between 1 minute and 3 minutes. It is still more 
preferred that the time be between 1 second and 30 seconds. 
It is most preferred that the time be between 1 second and five 
seconds 
Additionally, further EEG signal measurements from the 
regions of the Subject's brain that possess irregular activity 
are monitored during the administration of the therapy and the 
neurostimulation signal is adjusted based on any detected 
changes in the additional EEG signal measurements. The 
normalization of the EEG signals from the regions of the 
Subject's brain that possess irregular activity results in an 
alleviation of the symptoms of the neurological disorders. 
The neurostimulation signal comprises a carrier frequency 
which comprises the dominant frequency and the frequency 
offset. It is preferred that the frequency offset be between -10 
and 20 hertz. 
It is preferred that the normalization of the regions of the 
Subject's brain that possess irregular activity result in these 
regions transmitting EEG signals which are close to the pre 
determined frequency and amplitude expected for those 
regions of the subjects brain. It is even more preferred that 
these regions transmit EEG signals at the predetermined fre 
quency and amplitude expected for those regions of the Sub 
ject's brain after the treatment. 
The Subject may require multiple exposures to the method 
in order to achieve an alleviation of the symptoms he or she 
suffers from the neurological dysfunctions. It is preferred that 
the multiple exposures remain in the range of 1 to 40 expo 
Sures. However, more exposures are permitted, if required. It 
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is more preferred that the exposures remain in the range of 10 
to 30 exposures. It is more preferred that the exposures remain 
in the range of 5 to 10 exposures. Additionally, it is preferred 
that a repeated use of the method be avoided within 24 hours 
of a previous use of the method. However, if required, it is 
possible to treat more than one region of the subject’s brain (if 
more than one region of the Subjects brain possesses irregu 
lar activity) in one treatment session. 
Additionally, the Subject may be medicated, sedated, or 
unconscious during the administration of the method. How 
ever, it is preferred that the subject be in none of these con 
ditions. 
Regarding the application of the neurostimulation signal 
itself, after the identification of regions the subjects brain 
which possess irregular activity, neurostimulation treatment 
is accomplished by placing EEG sensors in an arrangement 
that allows for the measurement of the EEG activity from the 
dysfunctional region, as well for providing a successful deliv 
ery of current from the EEG sensors into a system ground. 
The computer-controlled system in the preferred embodi 
ment of the present invention acquires EEG signal data from 
the sensor sites and conducts an analysis of the EEG signal 
data to determine the frequency of the low frequency carrier 
signal component of the AMPWM signal. 
The AMPWM signal can be transmitted to the subject 
through a plurality of neurostimulation delivery modes. In a 
preferred embodiment of the present invention the preferred 
mechanism of delivery is accomplished by inducing the 
AMPWM signal into the EEG sensors through inductive cou 
pling. Another preferred mechanism is to use the AMPWM 
signal to drive a light-generating component. Such as a light 
emitting diode, to provide a photic stimulation signal that 
may be delivered to the patient through the optic nerve. 
Another preferred embodiment involves the simultaneous 
use of stimulation delivery by inducing the AMPWM signal 
into the EEG sensors through inductive coupling and drive a 
light-generating component, such as a light emitting diode, to 
provide a photic stimulation signal. In essence, this is a com 
bination of previously discussed embodiments. 
Lastly, it is preferred that EEG leads be placed on the scalp 
regardless of what stimulation method is used because the 
apparatus and method preferably measures EEG during 
stimulation delivery, and uses these EEG measurements to 
drive neurostimulation signal parameters. 
In a preferred embodiment of the present invention, deliv 
ery mode is selectable to account for different levels of sen 
sitivity and tolerance in patients. It is also possible to com 
pletely automate the process of transmitting the 
neurostimulation signal and the monitoring of the EEG signal 
data from the EEG sensors. 
As stated above, it is preferred that the EEG signals from 
the subject be measured at typically 21 different scalp loca 
tions and it is preferred that power spectral density computa 
tions are performed on the obtained EEG signals. These com 
putations break the measured analog EEG signals into 
frequency domain data such as a Fourier series of discrete 
frequency components, which is limited to 1-42 Hertz 
(greater signal components exist and could be utilized, but the 
1-42 Hertz range is typically considered clinically useful). 
However, other methods of obtaining the frequency domain 
data are acceptable (such as the use of wavelet analysis). 
In analyzing EEG signal data, frequency bands are com 
monly used. For example, the “delta” band is typically 1-4 
Hertz, the “theta' band is 5-7 Hertz, and so on. For each site, 
the total amplitude associated with each discrete frequency 
component is assigned to proper bands, providing a measure 














From this, a graphic “image' is generated where colors rep 
resent amplitudes. From this image, the clinician can see EEG 
band activity related to regions of the brain, and based on 
clinical knowledge, can determine if a region has unusual or 
abnormal activity. 
Accordingly, the neurostimulation phase of the process 
(i.e. treatment) is administered to correct regions of abnormal 
activity. The administration of the neurostimulation signal is 
preferably performed after the imaging process described 
above is completed. The clinician preferably applies EEG 
sensors to regions of the Scalp that relate to the regions of 
suspected dysfunction and the EEG signal data is preferably 
re-measured for a period long enough to provide power spec 
tral density data (as in the imaging process). The frequency 
domain data is then Sorted, and the frequency that exhibits the 
highest amplitude is designated the "dominant frequency’. 
According to clinician chosen stimulation time and frequency 
parameters, a neurostimulation signal is generated that has a 
“carrier frequency” that is determined by the formula: 
CARRIER FREQUENCY=DOMINANT FRE 
QUENCY+FREQUENCY OFFSET 
The parameters the clinician uses are (1) stimulation inten 
sity, (2) the times that the stimulation signal is turned on in the 
treatment cycle (as well as the number of times), (3) the 
duration that each stimulation signal is turned on, the leading 
frequency of each stimulation event, and (4) the phase offset 
of each stimulation event. Intensity is defined by the pulse 
width-modulation duty cycle, and ranges from 0 (no "on 
time') to 100% (no “off-time'). Thus, an intensity of 50% 
would have a duty cycle such that “on-time' is equal to 
“off-time' in each pulse cycle. The number of stimulation 
cycles and the times that the stimulation turns on is entirely 
clinician driven. However, it is preferred ranges that the 
stimulation cycles range between 1 Stimulation event up to 
50. It is preferred, however, that no more than 20 different 
stimulation events be used per session. The preferred leading 
frequency is already defined to range between -10 and 20 Hz. 
Preferred Phase offset ranges from -180 to 180 Hz. 
In this formula, “frequency offset is preferably selected 
from the range of -40 to 40 Hertz and more preferably from 
-10 and 20 Hertz. 
The offset is chosen by clinical experience, therefore, one 
of ordinary skill in the art would recognize how to choose an 
offset. However, the clinician generally picks the largest off 
set (i.e., +20 Hz) to see ifa response is elicited. If no response 
is elicited, lower offsets will be tried until a response is 
obtained. The clinician’s choice of parameter values is typi 
cally driven by a selection of choices that cause the subject to 
react, but yet do not cause an “over-reaction' which is an 
adverse effect characterized by short-term fatigue, headache, 
etc 
All of the preferred neurostimulation parameters to be 
considered are defined below. Values of these parameters are 
chosen based on clinician experience, and are selected in a 
manner that is meant to cause a reactive therapeutic effect 
without causing the subject to over-react. The selection of 
these values is further driven by subject condition and symp 
tomatic presentation. For example, a Subject with mild trau 
matic brain injury may be able tolerate a longer (in duration) 
than average stimulation application without Suffering an 
adverse effect. However, a subject with Fibromyalgia with 
severe fatigue may only tolerate a very short (in duration) 
stimulation burst at the lowest intensities possible. The ranges 
of values for these parameters are provided for the clinician to 
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choose based on experience, patient condition and symptom 
atic presentation, thus no preferred or optimal values exist. 
These parameters include: 
Intensity. This is a measure of the pulse width modulation 
signals duty cycle. This provides a variation on the time 
averaged current delivered to the stimulation mechanisms 
(i.e. the EEG lead inducing circuit and the photic stimulators). 
Duration. This is a measure the time in seconds that a 
neurostimulation event (i.e. a period of stimulation signal 
output) lasts. This can range from 1 second to 1,200 seconds 
in the preferred embodiment. 
Start Time This is the time in seconds after the beginning 
of a neurostimulation treatment session begins when a neu 
rostimulation event starts to occur. There is no specific limi 
tation on this, that is, the start time could begin at any time 
after the treatment session begins. Before the start time 
occurs, the system is simply measuring EEG and this could, 
theoretically, go on indefinitely. 
Leading Frequency and Phase Offset are previously 
defined. 
By adding the frequency offset to the dominant frequency, 
a carrier frequency is created that is always different than the 
dominant frequency. This neurostimulation signal is then 
either induced in the EEG sensors attached to the subjects 
Scalp or the neurostimulation signal is used to drive light 
emitting diodes for photic stimulation purposes. The duration 
of the signal, along with other parameters (as described 
above) such as intensity and phase offset (in the case of LEDs 
for photic stimulation—a phase offset causes the LEDs to 
flash out of synchronization with each other) are determined 
by the clinician's chosen treatment protocol. 
As described above, the neurostimulation signal can be an 
amplitude modulated pulse-width modulation signal. A 
graphic representation of the signal is shown in FIG. 2. In 
other words, the carrier frequency simply turns an electric 
signal on and off in a way that a square-wave pulse train is 
generated with a frequency equal to the carrier frequency. 
Thus, in a period (period=1/frequency) of this pulse train, 
there will be an amount of time that the electric signal is “on” 
and an amount of time when the signal is “off” (see FIG. 2). 
During the time that the carrier signal is “on”, the electricity 
is further pulsed at a very high frequency. A pulse width 
modulator is used to control this high frequency pulsing. By 
varying the pulse width, the average current applied is varied. 
This is what varying the “intensity” means. With a very low 
duty cycle, there is very little average current and thus the 
neurostimulation signal has very low intensity. Conversely, a 
higher duty cycle delivers more current and thus the intensity 
increases. A 100% duty cycle means that there is no “high 
frequency off time', and thus the entire neurostimulation 
signal is a simple square wave pulse train with frequency 
equal to the carrier frequency. 
Regarding the apparatus, FIG. 3 presents a model of the 
apparatus of the present invention. In FIG. 3., tissue imped 
ance 6 is represented by a parallel combination of a simple 
resistor 1 and a simple capacitor 2. A Voltage source 3 pro 
vides electricity at a supply electrode 4 interfaced at a sub 
jects skin 7, with the electricity passing through the tissue 
impedance 6 and ultimately being returned to a common 
ground 5 potential. Following fundamental circuit analysis, 
the equivalent impedance (Zor-Evr) of the circuit is 













ZEQUIVALENT = 1 + 2fRC 
In this formula, the resistance is given by the nomenclature 
R, capacitance by Cand frequency by f. This equation clearly 
shows that as the frequency of the signal increases, the overall 
impedance of the system decreases despite the level of imped 
ance from the resistor 1 being constant. Although the imped 
ances of the composite tissues of the head are considerably 
more complex and require a far more Sophisticated model to 
accurately describe current flows, this model provides a 
simple analogy and approximately describes the effect, and is 
a fundamental basis for the disclosure of the present inven 
tion. 
The effects of applying electrical energy to brain tissues, 
the electrical energy is known in this disclosure as a neuro 
stimulation signal, are well established in the medical litera 
ture and in other teachings, and will not be expounded upon 
here. 
As stated above, the invention is also directed to an appa 
ratus for neurostimulating a subject. The apparatus comprises 
a computing device that is operatively coupled to a neuro 
stimulator, and a series of EEG sensors that are coupled to the 
neurostimulator. Examples of appropriate computing devices 
are microprocessors or computers. However, any processing 
unit can be used in the present invention as a computing 
device. These components are coupled to each other via elec 
trical conduction paths. For example, the neurostimulator 
could be coupled to the computing device with RS232 cable, 
USB cable, etc. Further, the EEG sensors can be coupled to 
the neurostimulator with an electrical connector. However, in 
both instances, other methods of coupling the components are 
acceptable. The EEG sensors are configured (1) to be attached 
to the subject, (2) to monitor EEG signals of a subject, and (3) 
to administer neurostimulation signals to the Subject. Addi 
tionally, the EEG sensors comprise at least one positive con 
tact, at least one negative contact, and at least one ground 
COntact. 
The apparatus further comprises a biopotential acquisition 
device, at least one filtering unit, an isolation amplifier, and a 
microcontroller. A preferred microcontroller is the Toshiba 
TMP95EY64. However, any comparable microcontroller 
may be used. The biopotential device is operatively coupled 
to the computing device, and the neurostimulator is config 
ured to transmit the biopotential data and EEG signal data to 
the biopotential acquisition device. These components may 
be coupled together in the manner set forth previously or in 
any additional manner that permits their correct usage. Addi 
tionally, the biopotential acquisition device is configured to 
transmit the EEG data and biopotential data through at least 
one circuit or numerical filter and through an isolation ampli 
fier which is operatively coupled to the microcontroller. Fur 
thermore, it is preferred that the isolation amplifier be capable 
of performing “notch' filtering (i.e., eliminate 60 Hz line 
noise) and it can be selected from any component found on 
the market. It is preferred that it be a Burr-Brown ISO-100. 
It is preferred that the filtering unit be selected from the 
group consisting of a circuit configured to filter data and a 
numerical filter. It is also preferred that the biopotential acqui 
sition device is a biopotential amplifier or a high resolution 
analog-to-digital converter. 
The neurostimulator comprises a biopotential acquisition 
unit comprising an electric circuit configured to acquire bio 
potential data from the EEG signals obtained by the EEG 
sensors attached to the Subject. The biopotential acquisition 
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unit is also configured to analyze and store the acquired 
biopotential and EEG data with computational means and it is 
operatively coupled to the neurostimulator. The neurostimu 
lator also comprises a transmission unit configured to trans 
mit the biopotential and EEG data from the neurostimulator 
to the computing device and an I/O (input/output) unit con 
figured to adjust for a time lag in the biopotential and EEG 
data being transmitted. The neurostimulator also comprises at 
least one Switching unit configured to manage a neurostimu 
lation signal. 
It is preferred that the subject is a mammal. It is further 
preferred that the subject be a primate and even more pre 
ferred that the subject is a human being. It is also preferred 
that the Switching device is a transistor. 
Additionally, the neurostimulator comprises an inductor, 
acting as a transformer, whereas the stimulation signal is 
induced in the neurostimulator by inducing electrical current 
into the inductor, which further induces electrical current in 
the EEG sensors via electromagnetic coupling, and thereby 
into the subject. 
The neurostimulator can further comprise an optical unit 
which further comprises a set of light generating devices 
located in close proximity to the pupils of the subject. It is 
preferred that the light generating devices are light-emitting 
diodes. 
With reference to the accompanying FIG. 1, a preferred 
embodiment of the present invention is described where a 
computing device 8 is operatively coupled to a peripheral 
device henceforth referred to as a neurostimulator 9, such as 
through a peripheral cable 10. However, a peripheral cable is 
not the only method of coupling the neurostimulator to the 
computing device. The neurostimulator 9 further comprises a 
series of electrical conductors henceforth referred to as EEG 
sensors 11. The EEG sensors 11 consist of at least one positive 
lead 12, one negative lead 13 and one ground lead 14. How 
ever, the at least one positive lead 12, one negative lead 13. 
and one ground lead 14 may also be incorporated into one 
SensOraS COntactS. 
In a preferred embodiment of the present invention, 
employing multiple sets of EEG sensors 11 simultaneously 
and multiple biopotential acquisition devices 15 can accom 
plish acquisition of EEG signals from multiple sites on the 
scalp. For clarity, the preferred embodiment is described with 
for acquisition of EEG signal from one scalp site. All EEG 
sensors 11 are connected to the neurostimulator 9 via EEG 
sensor connectors 17. 
The neurostimulator 9 can further comprise, as a possible 
means of delivering the stimulation signal, an optical unit 16 
that is electrically coupled to the neurostimulator 9 via optical 
device sensors connectors 19. The optical unit 16 can be 
connected to the neurostimulator 9 by an optical device cable 
18. However, other means of connecting the optical unit to the 
neurostimulator are acceptable. The optical device further 
comprises light generating devices 20 located to be in close 
proximity to the subject’s eyes. In the preferred embodiment, 
the light generating devices 20 are light emitting diodes 21. 
The neurostimulator 9 is operated by any number of pos 
sible power Supply 22 Sources. To assure electrical isolation 
for the patient’s safety, an isolated power supply 23 is utilized 
in the preferred embodiment. Further, the neurostimulator 9 is 
housed in a protective outer enclosure 24. 
The neurostimulator 9 preferably internally comprises the 
biopotential acquisition device and the biopotential acquisi 
tion device is preferably designed to acquire biopotential data 
from EEG signal data, specifically patient EEG, to provide a 
means for analysis and data storage of the biopotential data 













signal and deliver the neurostimulation signal to the patient. It 
is preferred that a Teledyne A110-2 amplifier be used. 
In a preferred embodiment of the present invention, EEG 
signals are acquired with EEG sensors 11 attached to a 
patient’s scalp. At the end of the EEG sensors 11 attached to 
the patient are contact electrodes 25. The EEG signal is deliv 
ered to the neurostimulator 9 via the EEG sensors 11, con 
nected to the biopotential acquisition device 15 through EEG 
lead connectors 17 and operatively coupled to a biopotential 
acquisition device 15 Such as a biopotential amplifier or high 
resolution analog-to-digital converter. To minimize the effect 
of external electrical noise, any number of circuit or numeri 
cal filters 26 may be employed in the preferred embodiment. 
To assure patient safety, the biopotentials are passed through 
an isolation amplifier 27. The output of the biopotentials, after 
passing through the biopotential acquisition device 15, filters 
26 and isolation amplifier 27 is acquired by a microcontroller 
28 through analog-to-digital ports 29. The microcontroller 28 
is operatively coupled to the computing device 8. One method 
of coupling the microcontroller to the computing device is to 
use a peripheral cable 10. Control of the neurostimulator 9 is 
accomplished by communication between the microcontrol 
ler 28 and the computing device 8. Further, the objective of 
biopotential data analysis and storage is accomplished com 
putationally via communication between the microcontroller 
28 and the computing device 8. 
After analysis of the acquired biopotential, that is, the EEG 
signal, the computing device 8 communicates proper stimu 
lation signal parameters, in accordance with the present 
invention, to the microcontroller 28. These parameters 
include signal energy level, frequency of the low frequency 
component of an AMPWM signal, phase offset of multiple 
signals, start time, frequency offset and duration through a 
user interface. Utilizing a digital-to-analog port 30 on the 
microcontroller 28, the stimulation signal is output from the 
microcontroller 28 to transistors 31 or similar switching 
devices capable of managing the current levels of the stimu 
lation signal. Depending on the mode of Stimulation chosen 
by a clinician, the stimulation signal will be routed to the 
different means of stimulation signal delivery, alone or in 
combination. The parameters for the clinician’s choice are set 
forth above. 
If optical stimulation is desired, the stimulation signal will 
be sent to the optical unit 16 featuring the light generating 
devices 20 to be worn by the patient. Any unit capable of 
emitting light may be used as a light generating device. This 
includes, but is not limited to a LED, a lightbulb, a low-power 
laser, etc. Alternately, if EEG lead 11 stimulation is desired, 
where the stimulation signal is delivered to the patient's scalp 
via the attached electrodes 25, then the stimulation signal is 
sent to an inductor 32 which is designed to induce current in 
the EEG sensors 11 from the stimulation signal generated by 
the microcontroller 28. In the preferred embodiment of the 
present invention, a plurality of stimulation delivery modes is 
warranted to allow for clinician choice to further effect suc 
cessful treatment based on individual patient needs. 
To assure patient safety, all electronics in the neurostimu 
lator 9, including the biopotential acquisition device 15, the 
filter 26, the isolation amplifier 27, the microcontroller 28 and 
the transistors 31 are supplied electricity by the aforemen 
tioned isolation power supply 23. 
Finally, regarding the coupling of the components, if a 
computing device is used it is preferably operatively coupled 
to the processor of the neurostimulator via any of a number of 
means of commonly used peripheral communications tech 
niques, such as serial communication, USB port communi 
cation or parallel communication 10. All remaining electron 
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ics are preferably operatively coupled to the processing 
device (e.g. microcontroller) in the neurostimulator. The data 
acquisition circuit preferably comprises the biopotential 
acquisition device 15, filters 26 and isolation circuitry (ampli 
fier) 27. The isolation amplifier is preferably coupled to an 
analog-to-digital input port on the microcontroller 28, via 
electrical conduction paths. Such as wires or printed circuit 
board conductors. The filters 26 are preferably operatively 
coupled to the isolation amplifier 27 via electrical conduction 
paths such as wires or printed circuit board conductors. Fur 
ther, the biopotential acquisition device 15 is preferably 
operatively coupled to the filters 26 via electrical conduction 
paths such as wires or printed circuit board conductors. 
EEG leads 11 are preferably coupled to the biopotential 
acquisition device 15 via electrical connectors 17, providing 
conduction of EEG electricity at the scalp to the biopotential 
amplifier 15. 
A stimulation circuit is preferably coupled to a digital-to 
analog port 30 on the microcontroller, in all cases via electri 
cal conduction paths. Such as wires or printed circuit board 
conductors. It is preferred that an isolated power supply 23 
Supplies all operative power for neurostimulation outputs 
such as that to the optical device 16 or the EEG lead stimu 
lation inducing circuitry 32. Electrical output from the digi 
tal-to-analog port30 is preferably conducted to a transistor 31 
that is further coupled to the isolated power supply 23. When 
a signal is received at the base of the transistor 31 from the 
microcontroller 28, the transistor operates to switch on elec 
tricity from the isolated power supply 23 which is further 
conducted via electrical coupling to the inductor (stimulation 
inducing circuitry) 32. Current flow in the inductor 32 
induces a current in the EEG lead, as described in the speci 
fication. 
Alternately, for photic stimulation, the isolated power Sup 
ply 23 is preferably coupled via electrical coupling to two 
more transistors 31, which are preferably operatively coupled 
via electrical coupling to independent digital-to-analog ports 
30 on the microcontroller 28. Electricity conducted from the 
digital-to-analog ports 30 to the base of the transistors 31 in 
the photic stimulation circuit has the effect of switching on 
these transistors, further allowing for conduction of electric 
ity to the photic stimulation devices, such as LEDs 21. The 
photic stimulation devices are preferably coupled to the tran 
sistors 31 via electrical connectors 19, thus providing for 
current flow to the photic stimulation devices such as LEDs 
21. 
Finally, it is preferred that the apparatus operate on a 12 
Volt power Supply. It is more preferred that the apparatus 
operate on a 6 volt power supply. It is most preferred that the 
apparatus operate on a power Supply equivalent to the lowest 
power Supply requirement of the components used. 
The following references are incorporated by reference in 
their entirety: 
1. “High-frequency stimulation of the subthalamic nucleus 
silences Subthalamic neurons: a possible cellular mecha 
nism in Parkinson's Disease', Magarinos-Ascone C, Pazo 
J H Macadar O and Buno W. (Neuroscience 2002: 115(4): 
1109-17. 
2. “The spatial receptive field of thalamic inputs to single 
cortical simple cells revealed by the interaction of visual 
and electrical stimulation', Kara, Pezaris J. S. Yurgenson S 
and Reid, R. C. Proc Natl Acad Sci USA 2002 Dec. 10; 
99(25): 16261-6. 
3. “The anticonvulsant effect of electrical fields'. Weinstein 
S. Curr Neurol Neurosci Rep 2001 March; 1(2): 155-61. 
4. "Electrical stimulation of the motor cortex in neuropathic 














5. "Centromedian-thalamic and hippocampal electrical 
stimulation for the control of intractable epileptic sei 
Zures’, Velasco M, Velasco F, Velasco A. L. J. Clin Neuro 
physiol 2001 November; 18(6):495-513 
We claim: 
1. A system for providing external electrical stimulation 
and treatment for a disorder by electrically stimulating and 
treating neurological tissue of a region of a brain, the system 
comprising: 
means for generating an amplitude-modulated pulse-width 
modulation (AMPWM) signal, the AMPWM signal 
including a high frequency signal component and a low 
frequency signal component, wherein the high fre 
quency signal component is amplitude-modulated and 
pulse-width modulated, wherein the high frequency sig 
nal component has a sufficiently high frequency to 
enable the AMPWM signal to penetrate high impedance 
portions of tissue located between external EEG sensors 
placed on a scalp and the neurological tissue of the 
region of the brain being stimulated, wherein the low 
frequency signal component is of Sufficiently low fre 
quency to provide the electrical stimulation and treat 
ment, and wherein the low frequency signal component 
dynamically varies in frequency over time; and 
means for transmitting the AMPWM signal from a neuro 
stimulation device to the neurological tissue of the 
region of the brain being stimulated via the external EEG 
sensors placed on the scalp. 
2. The system of claim 1, wherein the neurostimulation 
device and EEG sensors are externally located relative to the 
tissue and the neurological tissue of the region of the brain. 
3. The system of claim 1, wherein the disorder to be treated 
is a neurological disorder. 
4. The system of claim 1, further comprising means for 
simultaneously providing electrical stimulation and measur 
ing of an overlapping Voltage. 
5. The system of claim 4, wherein the overlapping voltage 
is an electroencephalogram (EEG) signal. 
6. A system for providing external electrical stimulation 
and treatment for a disorder by electrically stimulating and 
treating neurological tissue of a region of a brain, the system 
comprising: 
a signal generator for generating an amplitude-modulated 
pulse-width modulation (AMPWM) signal, the gener 
ated AMPWM signal including a high frequency signal 
component and a low frequency signal component, 
wherein the high frequency signal component is ampli 
tude-modulated and pulse-width modulated, wherein 
the high frequency signal component has a Sufficiently 
high frequency to enable the generated AMPWM signal 
to penetrate high impedance portions of tissue located 
between external EEG sensors placed on a scalp and the 
neurological tissue of the region of the brain being 
stimulated, wherein the low frequency signal compo 
nent is of sufficiently low frequency to provide the elec 
trical stimulation and treatment; and 
a transmission device coupled to the signal generator, 
wherein the transmission device transmits an electrical 
stimulation and treatment signal from the generated 
AMPWM signal, and wherein the transmitted electrical 
stimulation and treatment signal is communicated from 
the neurostimulation device to the neurological tissue of 
the region of the brain being stimulated via the external 
EEG sensors placed on the scalp to electrically stimulate 
and treat the disorder. 
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7. The system of claim 6, wherein the neurostimulation 
device and EEG sensors are externally located relative to the 
tissue and the neurological tissue of the region of the brain to 
be treated. 
8. The system of claim 6, wherein the low frequency signal 
component dynamically varies in frequency over time. 
9. The system of claim 6, wherein the disorder to be treated 
is a neurological disorder. 
10. The system of claim 6, wherein the electrical stimula 
tion and treatment signal includes an external stimulation 
signal that drives an external stimulation device. 
11. The system of claim 10, wherein the external stimula 
tion device is an audio stimulation device. 
12. The system of claim 10, wherein the external stimula 
tion device is an optic stimulation device. 
13. The system of claim 10, further comprising: 
a processor coupled to the signal generator, the processor 
being capable of controlling the signal generator. 
14. The system of claim 13, further comprising: 
a sensor coupled to the processor, the sensor being capable 
of receiving information from at least one reference site 
of the tissue located between the neurostimulation 
device and the neurological tissue of the region of the 
brain being stimulated, wherein information from the 
sensor is a parameter in determining the AMPWM sig 
nal. 
15. The system of claim 14, wherein the sensor coupled to 
the processor is a lead for the neurostimulation device that 





16. The system of claim 15, wherein the sensor coupled to 
the processor and the lead for the transmission is the electro 
encephalogram (EEG) sensor. 
17. The system of claim 15, wherein the system is capable 
of simultaneous electrical stimulation and receipt of informa 
tion from the at least one reference site of the tissue located 
between the neurostimulation device and the neurological 
tissue of the region of the brain. 
18. The system of claim 14, wherein the sensor is capable 
of receiving electroencephalogram (EEG) information. 
19. The system of claim 1, wherein the high frequency 
signal component is in the range of 43 hertz to 1,000,000 hertz 
and the low frequency signal component is in the range of 1 
hertz -43 hertz. 
20. The system of claim 19, wherein the high frequency 
signal component is in the range of 1,000 hertz -100,000 
hertz. 
21. The system of claim 19, wherein the high frequency 
signal component is in the range of 10,000 hertz -20,000 
hertz. 
22. The system of claim 6, wherein the high frequency 
signal component is amplitude-modulated and pulse-width 
modulated so as to control a time-averaged current of the 
AMPWM signal when passing through a conducting 
medium, wherein the conducting medium comprises the tis 
Sue located between the external EEG sensors placed on the 
Scalp and the neurological tissue of the region of the brain 
being stimulated. 
